First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations

The efficacy of checkpoint inhibitors for non-small cell lung cancer (NSCLC) with MET exon 14 skipping (MET Δ14ex) remains controversial.

Source: European Journal of Cancer - January 15, 2024 Category: Cancer & Oncology Authors: Miriam Blasi, Jonas Kuon, Heike L üders, Daniel Misch, Diego Kauffmann-Guerrero, Moritz Hilbrandt, Daniel Kazdal, Roger-Fei Falkenstern-Ge, Björn Hackanson, Sebastian Dintner, Martin Faehling, Martina Kirchner, Anna-Lena Volckmar, Hans-Georg Kopp, Micha Tags: Original Research Source Type: research